This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergmann, M. Articles by Muster, T. Search for Related Content PubMed PubMed Citation Articles by Bergmann, M. Articles by Muster, T.

A Genetically Engineered Influenza A Virus with ras-Dependent Oncolytic Properties¹

Departments of Surgery [M. B., I. R., M. S., R. F., R. J.] and Dermatology [I. R., K. W., H. P., T. M.], University of Vienna Medical School, 1090 Vienna, Austria, and Department of Microbiology [A. G-S., P. P.], Mount Sinai School of Medicine, New York, New York 10029

The NS1 protein of influenza virus is a virulence factor that counteracts the PKR-mediated antiviral response by the host. As a consequence, influenza NS1 gene knockout virus delNS1 (an influenza A virus lacking the NS1 open reading frame) fails to replicate in normal cells but produces infectious particles in PKR-deficient cells. Because it is known that oncogenic ras induces an inhibitor of PKR, we addressed the question of whether the delNS1 virus selectively replicates in cells expressing oncogenic ras. We show that upon transfection and expression of oncogenic N-ras, cells become permissive for productive delNS1 virus replication, suggesting that the delNS1 virus has specific oncolytic properties. Viral growth in the oncogenic ras-transfected cells is associated with a reduction of PKR activation during infection. Moreover, treatment of s.c. established N-ras-expressing melanomas in severe combined immunodeficiency mice with the delNS1 virus revealed that this virus has tumor-ablative potentials. The delNS1 virus does not replicate in nonmalignant cell lines such as melanocytes, keratinocytes, or endothelial cells. The apathogenic nature of the delNS1 virus combined with the selective replication properties of this virus in oncogenic ras-expressing cells renders this virus an attractive candidate for the therapy of tumors with an activated ras-signaling pathway.

This article has been cited by other articles:

				S. L. Christian, T. W. Collier, D. Zu, M. Licursi, C. M. Hough, and K. Hirasawa Activated Ras/MEK Inhibits the Antiviral Response of Alpha Interferon by Reducing STAT2 Levels J. Virol., July 1, 2009; 83(13): 6717 - 6726. [Abstract] [Full Text] [PDF]

				Z. Xing, C. J. Cardona, S. Adams, Z. Yang, J. Li, D. Perez, and P. R. Woolcock Differential regulation of antiviral and proinflammatory cytokines and suppression of Fas-mediated apoptosis by NS1 of H9N2 avian influenza virus in chicken macrophages J. Gen. Virol., May 1, 2009; 90(5): 1109 - 1118. [Abstract] [Full Text] [PDF]

				B. G. Hale, R. E. Randall, J. Ortin, and D. Jackson The multifunctional NS1 protein of influenza A viruses J. Gen. Virol., October 1, 2008; 89(10): 2359 - 2376. [Abstract] [Full Text] [PDF]

				C Massard, E Deutsch, and J-C Soria Tumour stem cell-targeted treatment: elimination or differentiation Ann. Onc., November 1, 2006; 17(11): 1620 - 1624. [Abstract] [Full Text] [PDF]

				S. M. Battcock, T. W. Collier, D. Zu, and K. Hirasawa Negative Regulation of the Alpha Interferon-Induced Antiviral Response by the Ras/Raf/MEK Pathway J. Virol., May 1, 2006; 80(9): 4422 - 4430. [Abstract] [Full Text] [PDF]

				C. L. Efferson, N. Tsuda, K. Kawano, E. Nistal-Villan, S. Sellappan, D. Yu, J. L. Murray, A. Garcia-Sastre, and C. G. Ioannides Prostate Tumor Cells Infected with a Recombinant Influenza Virus Expressing a Truncated NS1 Protein Activate Cytolytic CD8+ Cells To Recognize Noninfected Tumor Cells J. Virol., January 1, 2006; 80(1): 383 - 394. [Abstract] [Full Text] [PDF]

				C. Kittel, B. Ferko, M. Kurz, R. Voglauer, S. Sereinig, J. Romanova, G. Stiegler, H. Katinger, and A. Egorov Generation of an Influenza A Virus Vector Expressing Biologically Active Human Interleukin-2 from the NS Gene Segment J. Virol., August 15, 2005; 79(16): 10672 - 10677. [Abstract] [Full Text] [PDF]

				J. H. Connor, C. Naczki, C. Koumenis, and D. S. Lyles Replication and Cytopathic Effect of Oncolytic Vesicular Stomatitis Virus in Hypoxic Tumor Cells In Vitro and In Vivo J. Virol., September 1, 2004; 78(17): 8960 - 8970. [Abstract] [Full Text] [PDF]

				M. Cascallo, G. Capella, A. Mazo, and R. Alemany Ras-dependent Oncolysis with an Adenovirus VAI Mutant Cancer Res., September 1, 2003; 63(17): 5544 - 5550. [Abstract] [Full Text] [PDF]

				C. L. Efferson, J. Schickli, B. K. Ko, K. Kawano, S. Mouzi, P. Palese, A. Garcia-Sastre, and C. G. Ioannides Activation of Tumor Antigen-Specific Cytotoxic T Lymphocytes (CTLs) by Human Dendritic Cells Infected with an Attenuated Influenza A Virus Expressing a CTL Epitope Derived from the HER-2/neu Proto-Oncogene J. Virol., July 1, 2003; 77(13): 7411 - 7424. [Abstract] [Full Text] [PDF]

				O. Ebert, K. Shinozaki, T.-G. Huang, M. J. Savontaus, A. Garcia-Sastre, and S. L. C. Woo Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-competent Rats Cancer Res., July 1, 2003; 63(13): 3605 - 3611. [Abstract] [Full Text] [PDF]

				K. Suzuki, R. Alemany, M. Yamamoto, and D. T. Curiel The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses Clin. Cancer Res., November 1, 2002; 8(11): 3348 - 3359. [Abstract] [Full Text] [PDF]